INDIA— Cadila Pharmaceuticals, based in Ahmedabad, India, has introduced the Cadiflu Tetra Vaccine, an innovative Quadrivalent Influenza Vaccine, to prevent influenza, a recurrent, widespread, and devastating viral infection. 

The Drug Controller General of India (DCGI) has authorized this quadrivalent influenza vaccine for use in adults and children.

It targets four influenza virus subtypes A and B, which cause seasonal epidemics, providing broader protection against seasonal flu.

This vaccine which has been developed utilizing cutting-edge proprietary technology and Nano-size particles, imitates the virus’s surface structure without having intact genetic material.

The Cadiflu Tetra Vaccine is intended to limit the occurrence of influenza sickness, lower the severity of the disease in those who become ill, and reduce the spread of infection to others.

The vaccine also has the potential to improve pregnant women’s influenza protection, benefiting both the mother and the child, according to the press release.

Influenza, often known as seasonal flu, is a highly contagious respiratory infection caused by influenza viruses.

These episodes can happen anywhere in the world at any time of year, and they frequently involve many waves that persist for an extended length of time.

Dr. Rajiv I Modi, Chairman and Managing Director of Cadila Pharmaceuticals, stated that their dedication to developing healthcare has prompted them to develop the Cadiflu Tetra Vaccine to serve the increasing needs of patients worldwide, utilizing next-generation technologies.

He went on to state that influenza is a global concern, and their goal is to deliver a strong solution that not only protects vulnerable populations but also contributes to the overall development of public health defences against influenza outbreaks.

The vaccine carries hemagglutinin (HA), neuraminidase (NA), and matrix 1 (M1) proteins from the individual strains aggregated together in a single formulation, according to a company release. 

The VLP vaccine replicates the viruses’ surface form but contains no live genetic material that can cause viral replication and infection.

Cadila believes that this vaccine is qualitatively superior and has a safer profile.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook.